A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.
Launched by HOFFMANN-LA ROCHE · Jul 19, 2007
Trial Information
Current as of July 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients, \>=18 years of age;
- • active rheumatoid arthritis;
- • receiving outpatient treatment;
- • an inadequate response, or intolerance, to \>=1 anti-TNF agent.
- Exclusion Criteria:
- • other rheumatic autoimmune disease or inflammatory joint disease;
- • concurrent treatment with any anti-TNF-alpha therapy;
- • joint or osseous surgery during 8 weeks prior to recruitment.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taoyuan, , Taiwan
Changhua, , Taiwan
Kaohsiung, , Taiwan
Tapei, , Taiwan
Taipei, , Taiwan
Taichung, , Taiwan
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials